SHIFT Newsroom · UK
Domperidone warning strengthened for rare adrenal tumour
The MHRA has added a restriction for confirmed or suspected phaeochromocytoma after reports of severe hypertension.
The UK medicines regulator has strengthened domperidone product information following a safety review involving people with phaeochromocytoma, a rare adrenal-gland tumour. Its 21 July 2026 notice says the medicine is contraindicated when the condition is confirmed or suspected because of the risk of severe rises in blood pressure.
A European review considered four reports. The MHRA said it had received no UK Yellow Card reports of this particular combination of medicine, condition and reaction at the time of the notice. Those figures describe reported events; they do not establish an individual patient's likelihood of harm.
The UK pharmacovigilance advisory committee supported the restriction. The notice also highlights that a severe blood-pressure episode after domperidone may reveal a previously unrecognised tumour, making clinical assessment important.
Domperidone is used for nausea and vomiting. The update reinforces existing limits on its use and identifies specific considerations for palliative care. It is a targeted safety change, rather than a withdrawal of every domperidone product. The regulator's notice contains the detailed professional and patient advice, including circumstances requiring urgent medical attention. Treatment decisions belong with the patient's clinical team.
Known facts
- Restriction covers confirmed or suspected phaeochromocytoma.
- European review: four reports; UK reports: none cited at publication.
- The notice concerns all domperidone product information.